Shots:
- AVITA Medical has launched Cohealyx, collagen-based dermal matrix in the US
- Cohealyx is currently being evaluated in the post-market Cohealyx I trial (enrolment ongoing) to further assess clinical outcomes, wound bed preparation for definitive closure, & patient recovery timelines
- Cohealyx, developed by AVITA & Regenity Biosciences, is designed to support cellular migration & revascularization, allowing formation of an optimal wound bed for closure, with preclinical & early clinical data showing integrated wound bed formation as early as 7 days
Ref: Globenewswire | Image: AVITA Medical
Related News:- The US FDA Grants 510(k) Clearance to Medivis’ Spine Navigation Platform
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
